Clinical Trials Directory

Trials / Terminated

TerminatedNCT01408836

Plasma Exchange for Renal Vasculitis

Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis

Status
Terminated
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
150 (actual)
Sponsor
Cambridge University Hospitals NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to test whether additional therapy with plasma exchange improves the chances of kidney recovery in severe kidney vasculitis.

Detailed description

Primary systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens (ANCA), is the most frequent cause of rapidly progressive glomerulonephritis. Renal failure at presentation often progresses to end stage renal disease despite immunosuppressive therapy. We investigated whether the addition of plasma exchange was more effective than intravenous (IV) methyl prednisolone in the achievement of renal recovery for ANCA associated systemic vasculitis presenting with a serum creatinine above 500umol/l (5.8mg/dl). 137 patients with a new diagnosis of ANCA associated systemic vasculitis, serum creatinine above 500umol/l (5.8mg/dl) and a renal biopsy demonstrating a focal, necrotizing glomerulonephritis were randomized to receive seven plasma exchanges or IV methyl prednisolone 1000mg/day for three days. Both groups were treated with cyclophosphamide and oral prednisolone. The primary end-point was dialysis independence with a serum creatinine below 500umol/l (5.8mg/dl) at three months. Secondary end-points included renal and patient survival at 12 months and severe adverse event rates.

Conditions

Interventions

TypeNameDescription
PROCEDUREPlasma exchangePlasma exchange
DRUGIntravenous methyl prednisoloneIntravenous methyl prednisolone
DRUGMethyl prednisolonemethyl prednisolone

Timeline

Start date
1995-03-01
Primary completion
2003-06-01
Completion
2003-12-01
First posted
2011-08-03
Last updated
2011-08-03

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01408836. Inclusion in this directory is not an endorsement.